An Overview on Candida auris in Healthcare Settings
Candida auris has become a major concern in critical care medicine due to the increasing number of immunocompromised patients and candidiasis is the most frequent cause of fungal infections. C. auris and other fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year. In immunocompromised patients, infections can quickly become severe, causing wound infections, otitis and candidemia, resulting in high morbidity and mortality. The clinical presentation of C. auris is often non-specific and similar to other types of systemic infections; in addition, it is harder to identify from cultures than other, more common types of Candida spp. Some infections are particularly difficult to treat due to multi-resistance to several antifungal agents, including fluconazole (and other azoles), amphotericin B and echinocandins. This entails treatment with more drugs and at higher doses. Even after treatment for invasive infections, patients generally remain colonized for long periods, so all infection control measures must be followed during and after treatment of the C. auris infection. Screening patients for C. auris colonization enables facilities to identify individuals with C. auris colonization and to implement infection prevention and control measures. This pathogenic fungus shows an innate resilience, enabling survival and persistence in healthcare environment and the ability to rapidly colonize the patient's skin and be easily transmitted within the healthcare setting, thus leading to a serious and prolonged outbreak.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Journal of fungi (Basel, Switzerland) - 9(2023), 9 vom: 08. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cristina, Maria Luisa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antifungal resistance |
|---|
| Anmerkungen: |
Date Revised 03.10.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jof9090913 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362513449 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362513449 | ||
| 003 | DE-627 | ||
| 005 | 20231226091411.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jof9090913 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362513449 | ||
| 035 | |a (NLM)37755021 | ||
| 035 | |a (PII)913 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cristina, Maria Luisa |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An Overview on Candida auris in Healthcare Settings |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.10.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Candida auris has become a major concern in critical care medicine due to the increasing number of immunocompromised patients and candidiasis is the most frequent cause of fungal infections. C. auris and other fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year. In immunocompromised patients, infections can quickly become severe, causing wound infections, otitis and candidemia, resulting in high morbidity and mortality. The clinical presentation of C. auris is often non-specific and similar to other types of systemic infections; in addition, it is harder to identify from cultures than other, more common types of Candida spp. Some infections are particularly difficult to treat due to multi-resistance to several antifungal agents, including fluconazole (and other azoles), amphotericin B and echinocandins. This entails treatment with more drugs and at higher doses. Even after treatment for invasive infections, patients generally remain colonized for long periods, so all infection control measures must be followed during and after treatment of the C. auris infection. Screening patients for C. auris colonization enables facilities to identify individuals with C. auris colonization and to implement infection prevention and control measures. This pathogenic fungus shows an innate resilience, enabling survival and persistence in healthcare environment and the ability to rapidly colonize the patient's skin and be easily transmitted within the healthcare setting, thus leading to a serious and prolonged outbreak | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Candida auris | |
| 650 | 4 | |a antifungal resistance | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a healthcare infections | |
| 650 | 4 | |a prevention and control measures | |
| 700 | 1 | |a Spagnolo, Anna Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Sartini, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Carbone, Alessio |e verfasserin |4 aut | |
| 700 | 1 | |a Oliva, Martino |e verfasserin |4 aut | |
| 700 | 1 | |a Schinca, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Boni, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Pontali, Emanuele |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of fungi (Basel, Switzerland) |d 2014 |g 9(2023), 9 vom: 08. Sept. |w (DE-627)NLM25748468X |x 2309-608X |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:9 |g day:08 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jof9090913 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 9 |b 08 |c 09 | ||